Non-TNF biologic DMARDs

Non-TNF biologic DMARDs

Drug monograph · NCLEX study reference
Trade names	Rituxan, Actemra, Stelara, Cosentyx, Dupixent, Orencia, Kineret
Therapeutic class	Biologic immunomodulators
Pharmacologic class	Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1)
Onset / peak / duration	Effect over weeks; IV or SubQ by agent.
Half-life / level	Long; dosed at intervals from daily (anakinra) to every several weeks or months.
Routes	IV, SubQ
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	Supportive care; manage infusion reactions.
Pregnancy / lactation	Case by case under specialist guidance.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Non-TNF biologic DMARDs (brand names Rituxan, Actemra, Stelara, Cosentyx, Dupixent, Orencia, Kineret) — Biologic immunomodulators; Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1).

Identification

• Therapeutic class: Biologic immunomodulators.
• Pharmacologic class: Monoclonal antibodies and receptor antagonists targeting specific immune pathways (CD20, IL-6, IL-12/23, IL-17, IL-4/13, T-cell costimulation, IL-1).

Pharmacology

• Mechanism of action: Each blocks a specific immune target to reduce inflammation.
• Onset / peak / duration: Effect over weeks; IV or SubQ by agent.
• Half-life / therapeutic level: Long; dosed at intervals from daily (anakinra) to every several weeks or months.

Clinical use

• Indications: Rheumatoid arthritis, psoriasis and psoriatic arthritis, inflammatory bowel disease, atopic dermatitis and asthma (dupilumab), certain lymphomas and vasculitis (rituximab).
• Usual dose, route, frequency: IV infusion (rituximab, tocilizumab, some) or SubQ (others) at agent-specific intervals.
• Maximum dose / adjustments: Hold for serious infection; screen for tuberculosis and hepatitis as appropriate.

Safety

• Contraindications: Active serious infection; agent-specific cautions.
• Black box warning: Rituximab carries boxed warnings for fatal infusion reactions, severe mucocutaneous reactions, hepatitis B reactivation, and progressive multifocal leukoencephalopathy; tocilizumab carries a boxed warning for serious infections.
• Interactions: Other immunosuppressants (infection), live vaccines (avoid), tocilizumab affects CYP substrates.
• Pregnancy / lactation: Case by case under specialist guidance.
• High-alert: No.

Adverse effects

• Common side effects: Infusion or injection reactions, upper respiratory infections, headache.
• Serious effects to report: Serious infections, hepatitis B reactivation (rituximab), neurologic symptoms (PML), GI perforation (tocilizumab, with diverticulitis), conjunctivitis (dupilumab).
• Antidote / reversal: Supportive care; manage infusion reactions.

Nursing process

• Assessment before administration: Infection screening, hepatitis B status (rituximab), premedication for infusions, vaccination status.
• Interventions during therapy: Premedicate and monitor closely during rituximab infusions; avoid live vaccines; hold for infection.
• Monitor: Infusion reactions, infection, hepatitis (rituximab), neurologic status.
• Evaluation / expected outcome: Reduced disease activity.

Patient teaching

• Patient teaching: Report infections and infusion reactions; avoid live vaccines.
• Notify provider if: Fever or infection, severe infusion reaction, new neurologic symptoms.
• Administration tips: Infusion monitoring and premedication for IV agents; SubQ rotation for others.